facebook
Logo for: PursueCare

PursueCare Speaking at the National Conference on Addiction Disorders (NCAD East)

NCAD East takes place from August 15-18 at the Baltimore Marriott Waterfront. It is the premier continuing education conference for addiction, behavioral, and mental health professionals. The conference draws clinicians and executives alike, working to improve and refine patient care as well as develop sustainable and successful treatment organizations. Particular focus on new solutions to address the nationwide opioid epidemic is anticipated.

PursueCare (https://www.pursuecare.com) is a technology-enabled health services startup aiming to help solve the nation’s growing opioid epidemic. The company has launched a first-of-its-kind telehealth opioid addiction treatment platform available to patients through an iOS/Android mobile app, tablet, or computer. Patients can use PursueCare’s platform to access Medication-Assisted Treatment like Suboxone from qualified physicians, addiction counseling, and mail-order pharmacy services. PursueCare is actively bringing together providers into a network of programmatic evidence-based care. The platform offers a way to provide on-demand, interventive, and transitional care to patients coming from hospital inpatient and emergency department, primary care, and rural health clinic settings. It is also directly accessible by patients, or can be offered by insurance plans and employers as a means for lower cost and more personalized treatment at home.

PursueCare has formed nationwide low-cost lab and toxicology screening partnerships, and anticipates also bringing a number of machine-learning recovery self-help and peer-support resources to patients directly through its app. PursueCare is forming partnerships nationwide with treatment providers, insurance payors, hospitals, primary care, and rural health clinics in an effort to bring greater access to effective and evidence-based treatment to Kentucky, West Virginia, and other states that have been heavily impacted by opioids.